Peptipedia
ImmuneIn Clinical TrialsClinical Trials

LL-37

Also known as Cathelicidin, CAP18

A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.

Investigational - Clinical trials for wound healing
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

100-200 mcg daily

Frequency

Once daily

Duration

Variable by protocol

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 100-200 mcg daily via Subcutaneous injection or topical, Once daily. Dose range: 50-300 mcg daily. Duration: Variable by protocol.

Timing & Administration

Administer via Subcutaneous injection or topical. Frequency: Once daily.

Mechanism of Action

Directly eliminates bacteria, fungi, and certain viruses by compromising cell membrane integrity. Regulates immune function, facilitates wound repair, decreases inflammatory responses, and demonstrates activity against bacterial biofilms.

Research Summary

Evidence level: clinical trials. Clinical status: Investigational - Clinical trials for wound healing.

Side Effects & Safety

Important Warnings

  • Skin ulcers and burning reported
  • Potential autoimmune concerns.
Injection site reactions
skin toxicity
allergic reactions
histamine release potential
possible autoimmune contribution
high-dose toxicity concerns

References

No references available.

Related Peptides

Browse all →
Thymosin Alpha-1Immune

A naturally occurring thymic peptide that enhances immune function.

View profile
KPVImmune

A tripeptide derived from alpha-melanocyte stimulating hormone (α-MSH). Known for potent anti-inflammatory effects, particularly in the gut.

View profile
VIPImmune

A naturally occurring peptide exhibiting immunomodulatory and anti-inflammatory properties being investigated for ARDS, pulmonary hypertension, and autoimmune disorders.

View profile